DRB18 is a pan-GLUT (glucose transporters) inhibitor that inhibits growth and proliferation in several different cancer types with IC50 high nM range.
DRB18 inhibits growth and proliferation in about 90% of the 60 different cancer cell lines in 9 major cancer types. DRB18 treatment leads to significant changes in glucose-based metabolism in A549 lung cancer cells, including cell death via ER/oxidative stress and necrosis.[1]
DRB18 (10 mg/kg) treatment thrice a week significantly reduces growth in Xenograft A549 tumors.[1]
[1] Pratik Shriwas, et al. Cancer Res 2020;80(16 Suppl):Abstract nr 4191.